DOI: 10.1093/cid/ciag466 ISSN: 1058-4838
A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes
Jacobo Pardo-Seco, Carmen Rodriguez-Tenreiro-Sánchez, Iago Giné-Vázquez, Narmeen Mallah, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Martín Cribeiro González, Mónica Conde Pájaro, Juan-Manuel González-Pérez, Irene Rivero-Calle, Xabier Bello, Josefina L Razzini, Antonio Salas, Rebecca C Harris, Matthew M Loiacono, Robertus van Aalst, Manel Farre, Marine Dufournet, Niklas Dyrby Johansen, Daniel Modin, Tor Biering-Sørensen, Carmen Duran-Parrondo, Federico Martinón-TorresAbstract
The GALFLU trial showed a lower incidence of hospitalisation among adults aged 65-79 years randomised to high-dose inactivated influenza vaccine (HD-IIV) compared with standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated an >80% probability of benefit (rVE >10%) against influenza-or-pneumonia-related hospitalisation, supporting the benefit of HD-IIV over SD-IIV.